Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nuvelo has enrolled the first patient in a single-center, Phase I trial to determine the safety, tolerability and pharmacokinetics of escalating doses of NU172, a thrombin-inhibiting aptamer, in approximately 30 healthy male volunteers.
Subscribe to our email newsletter
NU172 is an aptamer designed to directly inhibit thrombin’s ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign materials. Specifically, NU172 is being studied for use as a potential short-acting anticoagulant during procedures such as coronary artery bypass graft surgery and percutaneous interventions.
Michael Levy, executive vice president of research and development for Nuvelo, said: “This proof-of-concept trial will allow us to quickly determine NU172’s potential to achieve rapid onset and offset of anticoagulation. We look forward to sharing top-line data from this trial in the first half of 2008.”